I am an attending physician in both the Blood and Marrow Transplantation and the Hematologic Malignancies sections. In addition to caring for patients, I am also interested in finding ways to stimulate the immune system to treat pediatric leukemias.
My research is in the development of a controlled method of immune stimulation that allows the body’s own immune defense system to recognize and kill leukemia cells. Some patients whose leukemia does not respond to chemotherapy go into remission following an infection. We certainly try hard to protect children from infection during cancer therapy; however, those children who develop infections and then go on to have spontaneous remissions are sending us an important message about how powerful the immune system can be in treating leukemia.
Immune stimulation may help children with chemotherapy-resistant leukemia and improve the effectiveness of current treatments without adding long-lasting toxicity. Furthermore, if we stimulate a child’s immune system to recognize leukemia, long-term immune memory may act like a vaccine, recognizing leukemia cells and preventing relapse for his or her lifespan. We are working with a national group to bring these treatments into clinical trials and continue to look for new ways to help the immune system fight leukemia.
While research is a very important and fulfilling part of my job, the reason I became a doctor is to help care for sick children. A cancer diagnosis turns a family’s world upside down and comes with a flood of new information that can feel overwhelming. I believe in open, honest communication with patients and parents, including being clear about when we don’t know the answers, what we can do to find out, and that we are here to support families through every step of the way. What I love most about working at CHOP are the interactions between patients, families, and staff – we work together to give our children the best possible care. We also have the tremendous privilege of working side-by-side with the world’s leaders in nearly every pediatric specialty.
I am fortunate to be a part of two wonderful subspecialty teams within Oncology. The Hematologic Malignancies (leukemia and lymphoma) and Transplant teams meet weekly to discuss every currently active patient to ensure that each child in our care has the benefit of many eyes, ears and minds. We are always thinking about ways we can improve patient care. CHOP is a very special place where state-of-the-art research meets comprehensive, family-centered patient care, and I’m proud to be a part of it.
- Education and Training
Oregon Health Sciences University, Portland, Ore., MD
The Children's Hospital of Philadelphia, Philadelphia, Pa., Pediatrics
The Children's Hospital of Philadelphia, Philadelphia, Pa., Pediatric Hematology-Oncology
McGill University, MA, Linguistics
Oregon Health Sciences University, Portland, Ore., MPH, Epidemiology and Biostatistics
- Titles and Academic Titles
Attending physician<br>Assistant professor, Perelman School of Medicine at the University of Pennsylvania
- Centers and Programs
Seif AE, Rheingold SR, Fisher BT, Huang Y-SV, Li Y, Kersun LS, et al. Pediatric acute lymphoblastic leukemia (ALL) induction mortality: a population-based report from the Pediatric Health Information Systems (PHIS) database,1999-2009 [abstract]. Pediatric Blood & Cancer (ASPHO Annual Meeting Abstracts); 2011;56(6): 895-1002.
Reid GSD, Seif AE, Grupp SA. Immunotherapy approaches for acute lymphoblastic leukemia: clues from pre-leukemia studies [abstract]. National Cancer Institute Immunotherapy in Pediatric Oncology Conference; 2010 Oct; Houston, TX.
Barrett DM, Seif AE, Carpenito C, June CH, Grupp SA, Reid GS. Bioluminescent tracking of mouse and human leukemia engraftment patterns: influence of host immunocompetence and source species. Blood (ASH Annual Meeting Abstracts), 2010;116: 2140.
Seif AE, Rheingold SR, Fisher BT, Huang Y-SV, Li Y, Kersun LS, et al. Induction mortality in pediatric acute lymphoblastic leukemia (ALL): a retrospective cohort analysis from the Pediatric Health Information Systems (PHIS) database, 1999-2009. Blood (ASH Annual Meeting Abstracts), 2010;116: 3239.
Seif AE, Barrett DM, Brown VI, Grupp SA, Reid GSD. Generation of long-term protection from acute lymphoblastic leukemia by an immune stimulant in a syngeneic murine model. American Association of Immunologists Annual Meeting; 2009 May; Seattle, WA.
Reid GSD, Seif AE, Grupp SA. Immune-mediated depletion of pre-leukemic cells delays disease onset in a murine spontaneous disease model. American Association of Immunologists Annual Meeting, 2009 May; Seattle, WA.
Seif AE, Barrett DM, Brown VI, Grupp SA, Reid GSD. Durable immune-mediated protection from acute lymphoblastic leukemia (ALL) is induced by CpG oligodeoxynucleotides in a syngeneic mouse model. American Society of Pediatric Hematology/Oncology; 2009 Apr; San Diego, CA.
Seif AE. Pediatric leukemia predisposition syndromes: clues to understanding leukemogenesis. Cancer Genet. 2011 May; 204(2011):227-44. Cited in PubMed: PMID 21665176. Read the abstract
Seif AE, Manno CS, Sheen C, Grupp SA, Teachey DT. Identifying Autoimmune Lymphoproliferative Syndrome (ALPS) in children with Evans syndrome: a multi-institutional study. Blood. 2010; 115: 2142-2145. Cited in PubMed: PMID 20068224. Read the article
Seif AE, Sutter JA, Rheingold SR. Secondary adrenal insufficiency in an infant after intrathecal triple chemotherapy. Pediatr Blood Cancer. 2010 Aug; 55(2):386-9. Cited in PubMed: PMID 20582966. Read the abstract
Teachey DT, Seif AE, Grupp SA. Advances in the management and understanding of Autoimmune Lymphoproliferative Syndrome (ALPS). Br J Haematol. 2010 Jan; 148(2):205-16. Epub 2009 Nov 23. Cited in PubMed: PMID 19930184. Read the article
Commander L, Seif AE, Rheingold SR. Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory pediatric T-cell lymphoblastic leukemia and lymphoma. Br J Haematol. 2010 Aug; 150(3):345-51. Cited in PubMed: PMID 20528871. Read the abstract
Seif AE, Reilly AF, Rheingold SR. Intrathecal liposomal cytarabine in relapsed or refractory infant and pediatric leukemias: The Children's Hospital of Philadelphia experience and review of the literature. J Pediatr Hematol Oncol. 2010 Nov; 32(8): e349-52. Cited in PubMed: PMID 20962675. Read the abstract
Seif AE, Barrett DM, Milone M, Brown VI, Grupp SA, Reid GSD. Long-term protection from syngeneic acute lymphoblastic leukemia by CpG ODN-mediated stimulation of innate and adaptive immune responses. Blood. 2009; 114(12):2459-66. Read the abstract
- Editorial and Academic Positions
2010-present, Editorial Advisory Board, Cytotherapy
2008 to present, Ad hoc reviewer, Biol Blood Marrow Transplant
2009-present, Leukemia & Lymphoma Clinical Committee
- Editorial and Academic Positions